Clinical Trial Update: Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine [Phase 2]

View source ↗

Summary

Phase 2 trial follow-up assesses two-year safety and immunogenicity of the GSK 257049 malaria vaccine in children, with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• GSK 257049 Vaccine (GSK-257049 vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Malaria | Phase 2 | Status: COMPLETED | Results posted: 2014-03-27